BioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, today announced that a Top Ten pharmaceutical company has entered into a five-year enterprise-wide agreement for BioClinica Optimizer to simulate and forecast clinical trial supply scenarios for their worldwide clinical trial operations. BioClinica Optimizer was selected for its flexibility to simulate and optimize large-scale, complex clinical trials while remaining cost effective for smaller, early phase studies.
BioClinica Optimizer is the world’s only clinical trial supply forecasting tool that both simulates and optimizes clinical supply chains. “Our mission is to offer best-in-class products and services to our customers,” said Peter Benton, President of BioClinica’s eClinical division. “Progressive companies seek the best available tools to design and support the complex logistics associated with global clinical trials. Six of the Top 10 pharmaceutical and biotech companies now use BioClinica Optimizer technology, with savings measured in millions of dollars.”
“This selection exemplifies client validation of our eClinical strategy,” said Mark Weinstein, CEO of BioClinica. “This organization was already a large imaging services client; now BioClinica will support new areas of their clinical trial processes. The client told us that with BioClinica Optimizer they anticipate better information for designing studies with faster study starts, a reduction in patient participation drop-off, reduced waste and overstocking and an overall cost savings with improved supply management. This is a win for both organizations.”
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control.The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.